Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives $17.33 Consensus Price Target from Brokerages

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has earned a consensus rating of “Buy” from the eight analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $17.50.

Separately, Zacks Investment Research raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a report on Tuesday.

NASDAQ:VNDA traded down $0.03 during midday trading on Thursday, hitting $17.55. The company’s stock had a trading volume of 3,886 shares, compared to its average volume of 464,355. The firm has a market cap of $976.45 million, a P/E ratio of 30.17 and a beta of 0.52. Vanda Pharmaceuticals has a fifty-two week low of $9.17 and a fifty-two week high of $21.86. The firm’s 50 day moving average is $16.93 and its 200-day moving average is $17.59.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. The firm had revenue of $67.90 million during the quarter, compared to the consensus estimate of $71.00 million. Vanda Pharmaceuticals had a return on equity of 7.04% and a net margin of 12.55%. On average, sell-side analysts anticipate that Vanda Pharmaceuticals will post 0.66 earnings per share for the current fiscal year.

In other news, insider Aranthan Jones II sold 7,250 shares of the stock in a transaction that occurred on Monday, July 26th. The stock was sold at an average price of $19.69, for a total value of $142,752.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Stephen Ray Mitchell sold 19,109 shares of the stock in a transaction on Thursday, September 9th. The shares were sold at an average price of $16.74, for a total value of $319,884.66. Following the completion of the transaction, the director now owns 15,200 shares in the company, valued at $254,448. The disclosure for this sale can be found here. Insiders have sold 48,963 shares of company stock worth $837,220 over the last ninety days. 6.10% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of VNDA. LSV Asset Management boosted its position in Vanda Pharmaceuticals by 40.3% during the second quarter. LSV Asset Management now owns 1,850,048 shares of the biopharmaceutical company’s stock valued at $39,794,000 after acquiring an additional 531,066 shares during the last quarter. Voloridge Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 1st quarter worth approximately $1,858,000. Shell Asset Management Co. boosted its holdings in Vanda Pharmaceuticals by 37.9% in the 1st quarter. Shell Asset Management Co. now owns 43,900 shares of the biopharmaceutical company’s stock worth $659,000 after buying an additional 12,068 shares during the period. BlackRock Inc. boosted its holdings in Vanda Pharmaceuticals by 2.2% in the 1st quarter. BlackRock Inc. now owns 10,033,270 shares of the biopharmaceutical company’s stock valued at $150,699,000 after purchasing an additional 218,673 shares during the period. Finally, E Fund Management Co. Ltd. bought a new position in Vanda Pharmaceuticals in the 1st quarter valued at $61,000.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals, Inc engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.

See Also: Death Cross

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with's FREE daily email newsletter.